Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019
Bio-Path Holdings, Inc. (BPTH)
Last bio-path holdings, inc. earnings: 11/14 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
biopathholdings.com
Company Research
Source: GlobeNewswire
HOUSTON, April 03, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced that data from pre-clinical studies supporting the potential of BP1003, a novel liposome-incorporated STAT3 oligodeoxynucleotide inhibitor, for the treatment of pancreatic cancer, non-small cell lung cancer (NSCLC) and acute myelogenous leukemia (AML) were presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2019 today in Atlanta, GA. The poster, entitled “BP1003, a Novel Liposome-Incorporated STAT3 Antisense Oligodeoxynucleotide Inhibitor,” was presented by Ana Tari Ashizawa, Ph.D., Vice President of Research and Development at Bio-Path. The poster highlights four antisense oligo sequences directed against STAT3 mRNA identified by Bio-Path and manufactured using DNAbilize® antisense RNAi
Show less
Read more
Impact Snapshot
Event Time:
BPTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPTH alerts
High impacting Bio-Path Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
BPTH
News
- Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study [Yahoo! Finance]Yahoo! Finance
- Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- Bio-Path announces $1.2M registered direct offering priced at-the-market [Seeking Alpha]Seeking Alpha
- Bio-Path Holdings, Inc. (NASDAQ: BPTH) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $40.00 price target on the stock.MarketBeat
BPTH
Earnings
- 11/14/23 - Beat
BPTH
Sec Filings
- 4/19/24 - Form 8-K
- 4/19/24 - Form 424B5
- 4/19/24 - Form 8-K
- BPTH's page on the SEC website